Dual-targeting compound and preparation method and application thereof
AssigneeYantai Lannacheng Biotechnology Co., Ltd.
InventorsXiaoyuan Chen, Pengfei Xu, Xiaoming Wu, Zhide Guo, Qingbao Yang, Xuejun Wen
Life of this patent
Estimating the term…
Loading patent…
AssigneeYantai Lannacheng Biotechnology Co., Ltd.
InventorsXiaoyuan Chen, Pengfei Xu, Xiaoming Wu, Zhide Guo, Qingbao Yang, Xuejun Wen
Estimating the term…
The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (1-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin αvβ3 target, can realize synergistic targeting of the FAP target and the integrin αvβ3 target in tumors, and has high uptake in tumors and long retention time in tumors. The present disclosure also provides a radionuclide labeled dual-targeting compound based on the dual-targeting compound, and a preparation method and application thereof in preparation of medicines for diagnosis or therapy of diseases characterized by overexpression of FAP and/or integrin αvβ3.
A dual-targeting compound, wherein the compound structurally contains ligand structures specifically binding to FAP and integrin αvβ3 at the same time, and the compound has the following structure shown in Formula (I):
A dual-targeting compound capable of being labeled with a radionuclide, wherein the compound structurally contains ligands specifically binding to FAP and integrin αvβ3 at the same time and a nuclide chelating structure, and the compound has the following structure shown in Formula (I-1) or Formula (I-2):
Dependencies are inferred from the claim text.